Figma Shares Indicated To Open $105/$110
On July 29, 2025, John Martin Docherty, President & CSO and director of Lexaria Bioscience Corp (NASDAQ: NASDAQ:LEXX), purchased 5,376 common shares of the company. The shares were bought at a price of $0.928, totaling $4,988.
Following the transaction, Docherty directly owns 5,376 common shares. Docherty also indirectly owns 54,075 shares through a private holding company. The micro-cap company, valued at $17.8 million, maintains a strong balance sheet with more cash than debt and a healthy current ratio of 3.9x.
Docherty also holds options to acquire 310,834 common shares. These options are exercisable at prices ranging from $1.04 to $3.00, with expiration dates between 2026 and 2030. InvestingPro subscribers can access 8 additional key insights about LEXX’s financial health and market position.
In other recent news, Lexaria Bioscience has reported interim results from its Phase 1b GLP-1-H24-4 study in Australia, focusing on its DehydraTECH technology’s application with semaglutide and tirzepatide. H.C. Wainwright has adjusted its price target for Lexaria Bioscience to $4.00 from $5.00, while maintaining a Buy rating, following these developments. The company also announced that its DehydraTECH technology can reduce side effects in leading GLP-1 weight loss and diabetes drugs, addressing significant challenges in patient retention due to adverse effects. Additionally, Lexaria has expanded its patent portfolio to 50, with new international patents, including one in Australia for epilepsy treatment methods, extending protection until 2044.
In collaboration news, Lexaria is advancing its drug delivery technology through ongoing developments with a pharmaceutical company, referred to as PharmaCO. Initial pre-clinical studies have been completed under a Material Transfer Agreement, although the results remain undisclosed. PharmaCO is interested in reviewing additional data from Lexaria’s independent human study, which is expected to be released starting in Q3 2025. These developments are part of Lexaria’s strategic planning discussions with PharmaCO, potentially leading to further collaborative human clinical studies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.